Global Oral Live Cholera Vaccines Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Oral Live Cholera Vaccines Market Research Report 2024
Live, orally administered, attenuated vaccine strains of Vibrio cholerae have many theoretical advantages over killed vaccines.
According to Mr Accuracy reports new survey, global Oral Live Cholera Vaccines market is projected to reach US$ 143.7 million in 2029, increasing from US$ 85 million in 2022, with the CAGR of 7.0% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Oral Live Cholera Vaccines market research.
Factors such as increasing incidence of cholera outbreaks, rising awareness about the disease and its prevention, and government initiatives to control cholera are driving market growth. Oral live cholera vaccines offer advantages such as ease of administration, cost-effectiveness, and potential for herd immunity. The market is characterized by the presence of both established pharmaceutical companies and emerging players. However, challenges such as vaccine storage and distribution requirements, limited accessibility in resource-constrained regions, and the need for cold chain maintenance may pose obstacles to market expansion.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Oral Live Cholera Vaccines market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
PaxVax
Sanofi
Valneva
EuBiologics
Shanghai United Cell Biotechnology
Vabiotech
Segment by Type
Euvichol- Plus
DUKORAL
Shanchol
Others
Prevention
Emergency Response
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Oral Live Cholera Vaccines report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Oral Live Cholera Vaccines market is projected to reach US$ 143.7 million in 2029, increasing from US$ 85 million in 2022, with the CAGR of 7.0% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Oral Live Cholera Vaccines market research.
Factors such as increasing incidence of cholera outbreaks, rising awareness about the disease and its prevention, and government initiatives to control cholera are driving market growth. Oral live cholera vaccines offer advantages such as ease of administration, cost-effectiveness, and potential for herd immunity. The market is characterized by the presence of both established pharmaceutical companies and emerging players. However, challenges such as vaccine storage and distribution requirements, limited accessibility in resource-constrained regions, and the need for cold chain maintenance may pose obstacles to market expansion.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Oral Live Cholera Vaccines market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
PaxVax
Sanofi
Valneva
EuBiologics
Shanghai United Cell Biotechnology
Vabiotech
Segment by Type
Euvichol- Plus
DUKORAL
Shanchol
Others
Segment by Application
Prevention
Emergency Response
Consumption by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Oral Live Cholera Vaccines report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices